ProCE Banner Activity

CheckMate 649: Updated Results From Phase III Trial of First-line Nivolumab + CT or Ipilimumab vs CT in Advanced Gastroesophageal Cancers

Slideset Download
Conference Coverage
With additional follow-up, nivolumab + CT continued to show an OS benefit over CT alone in previously untreated patients with advanced gastroesophageal cancers.

Released: September 28, 2021

Expiration: September 27, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc